cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2019-34-3-66-72cardiotomsk-815Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESМолекулярные аспекты патологической активации и дифференцировки вальвулярных интерстициальных клеток при развитии кальцинирующего аортального стенозаMolecular aspects of the pathological activation and differentiation of valvular interstitial cells during the development of calcific aortic stenosishttps://orcid.org/0000-0001-6099-0315КостюнинА. Е.KostyuninA. E.

канд. биол. наук, младший научный сотрудник, отдел экспериментальной и клинической кардиологии, лаборатория новых биоматериалов,

650002, Кемерово, Сосновый бульвар, 6

Cand. Sci. (Biol.), Junior Researcher, Department of Experimental and Clinical Cardiology, Laboratory of New Biomaterials,

6, Sosnoviy blvd., Kemerovo, 650000

rhabdophis_tigrina@mail.ruНаучно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийРоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation2019011120193436672Copyright © Костюнин А.Е., 20192019Костюнин А.Е.Kostyunin A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/815

Кальцинирующий аортальный стеноз (КАС) является самым распространенным пороком сердца. Патогенез этого заболевания сходен с атеросклеротическим процессом в сосудах. Известно, что главной движущей силой фиброзного ремоделирования и минерализации тканей аортального клапана (АК) являются активация и последующая дифференцировка клапанных интерстициальных клеток в остео- и миофибробластоподобные клетки. Тем не менее, стоящие за этими процессами молекулярные механизмы до сих пор слабо изучены. В настоящей статье собрана и проанализирована современная информация по данному вопросу, рассмотрены основные молекулярные пути, опосредующие патологическую дифференцировку клеток клапана, причины их активации.

Calcific aortic stenosis is the most common valvular heart disease. The pathogenesis of this disease is complex and resembles the atherosclerotic process in the blood vessels. It is known that valvular interstitial cell activation and subsequent differentiation into osteoblast- and myofibroblast-like cells is the main driving force of fibrous and calcified aortic valve tissue. However, the molecular mechanisms behind these processes are still not fully understood. Current information on this issue is collected and analyzed in this article. The main molecular pathways mediating the pathological differentiation of the valvular interstitial cells and the reasons for their activation are considered.

аортальный стенозклеткисигнальные путидифференцировкаaortic stenosiscellssignaling pathwayscellular differentiationРабота выполнена в рамках комплексной программы фундаментальных научных исследований СО РАН по фундаментальной теме НИИ КПССЗ № 0546-2015-0011 «Патогенетическое обоснование разработки имплантатов для сердечно-сосудистой хирургии на основе биосовместимых материалов, с реализацией пациент-ориентированного подхода с использованием математического моделирования, тканевой инженерии и геномных предикторов».ReferencesLindman B.R., Clavel M.A., Mathieu P., Iung B., Lancellotti P., Otto C.M. et al. Calcific aortic stenosis. Nat. Rev. Dis. Primers. 2016;3(2):16006. DOI: 10.1038/nrdp.2016.6.Lindman B.R., Clavel M.A., Mathieu P., Iung B., Lancellotti P., Otto C.M. et al. Calcific aortic stenosis. Nat. Rev. Dis. Primers. 2016;3(2):16006. DOI: 10.1038/nrdp.2016.6.Osnabrugge R.L., Mylotte D., Head S.J., van Mieghem N.M., Nkomo V.T., LeReun C.M. et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J. Am. Coll. Cardiol. 2013;62(11):1002–1012. DOI: 10.1016/j.jacc.2013.05.015.Osnabrugge R.L., Mylotte D., Head S.J., van Mieghem N.M., Nkomo V.T., LeReun C.M. et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J. Am. Coll. Cardiol. 2013;62(11):1002–1012. DOI: 10.1016/j.jacc.2013.05.015.D’Arcy J.L., Prendergast B.D., Chambers J.B., Ray S.G., Bridgewater B. Valvular heart disease: the next cardiac epidemic. Heart. 2011;97(2):91–93. DOI: 10.1136/hrt.2010.205096.D’Arcy J.L., Prendergast B.D., Chambers J.B., Ray S.G., Bridgewater B. Valvular heart disease: the next cardiac epidemic. Heart. 2011;97(2):91–93. DOI: 10.1136/hrt.2010.205096.Thaden J.J., Nkomo V.T., Enriquez-Sarano M. The global burden of aortic stenosis. Prog. Cardiovasc. Dis. 2014;56(6):565–571. DOI: 10.1016/j. pcad.2014.02.006.Thaden J.J., Nkomo V.T., Enriquez-Sarano M. The global burden of aortic stenosis. Prog. Cardiovasc. Dis. 2014;56(6):565–571. DOI: 10.1016/j. pcad.2014.02.006.Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. Heart J. 2017;38(36):2739–2791. DOI: 10.1093/eurheartj/ehx391.Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. Heart J. 2017;38(36):2739–2791. DOI: 10.1093/eurheartj/ehx391.Marquis-Gravel G., Redfors B., Leon M.B., Généreux P. Medical treatment of aortic stenosis. Circulation. 2016;134(22):1766–1784. DOI: 10.1161/CIRCULATIONAHA.116.023997.Marquis-Gravel G., Redfors B., Leon M.B., Généreux P. Medical treatment of aortic stenosis. Circulation. 2016;134(22):1766–1784. DOI: 10.1161/CIRCULATIONAHA.116.023997.Nishimura R.A., Otto C.M., Bonow R.O. Carabello B.A., Erwin J.P., Fleisher L.A. et al. 2017 AHA/ACC focused update of the 2014 AHA/ ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25):e1159–e1195. DOI: 10.1161/CIR.0000000000000503.Nishimura R.A., Otto C.M., Bonow R.O. Carabello B.A., Erwin J.P., Fleisher L.A. et al. 2017 AHA/ACC focused update of the 2014 AHA/ ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25):e1159–e1195. DOI: 10.1161/CIR.0000000000000503.Schoen F.J. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation.2008;118(18):1864–1880. DOI: 10.1161/CIRCULATIONAHA.108.805911.Schoen F.J. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation.2008;118(18):1864–1880. DOI: 10.1161/CIRCULATIONAHA.108.805911.Rutkovskiy A., Malashicheva A., Sullivan G., Bogdanova M., Kostareva A., Stensløkken K.O. et al. Valve interstitial cells: the key to understanding the pathophysiology of heart valve calcification. J. Am. Heart Assoc. 2017;6(9):e006339. DOI: 10.1161/JAHA.117.006339.Rutkovskiy A., Malashicheva A., Sullivan G., Bogdanova M., Kostareva A., Stensløkken K.O. et al. Valve interstitial cells: the key to understanding the pathophysiology of heart valve calcification. J. Am. Heart Assoc. 2017;6(9):e006339. DOI: 10.1161/JAHA.117.006339.Hortells L., Sur S., Hilaire C. Cell рhenotype transitions in сardiovascular сalcification. Front. Cardiovasc. Med. 2018;5:27. DOI: 10.3389/fcvm.2018.00027.Hortells L., Sur S., Hilaire C. Cell рhenotype transitions in сardiovascular сalcification. Front. Cardiovasc. Med. 2018;5:27. DOI: 10.3389/fcvm.2018.00027.Mahler G.J., Farrar E.J., Butcher J.T. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2013;33(1):121–130. DOI: 10.1161/ATVBAHA.112.300504.Mahler G.J., Farrar E.J., Butcher J.T. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2013;33(1):121–130. DOI: 10.1161/ATVBAHA.112.300504.Witt W., Jannasch A., Burkhard D., Christ T., Ravens U., Brunssen C. et al. Sphingosine-1-phosphate induces contraction of valvular interstitial cells from porcine aortic valves. Cardiovasc. Res. 2012;93(3):490–497. DOI: 10.1093/cvr/cvs002.Witt W., Jannasch A., Burkhard D., Christ T., Ravens U., Brunssen C. et al. Sphingosine-1-phosphate induces contraction of valvular interstitial cells from porcine aortic valves. Cardiovasc. Res. 2012;93(3):490–497. DOI: 10.1093/cvr/cvs002.Latif N., Sarathchandra P., Chester A.H., Yacoub M.H. Expression of smooth muscle cell markers and co-activators in calcified aortic valves. Eur. Heart J. 2015;36(21):1335–1345. DOI: 10.1093/eurheartj/eht547.Latif N., Sarathchandra P., Chester A.H., Yacoub M.H. Expression of smooth muscle cell markers and co-activators in calcified aortic valves. Eur. Heart J. 2015;36(21):1335–1345. DOI: 10.1093/eurheartj/eht547.Yip C.Y., Simmons C.A. The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovasc. Pathol. 2011;20(3):177–182. DOI: 10.1016/j.carpath.2010.12.001.Yip C.Y., Simmons C.A. The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovasc. Pathol. 2011;20(3):177–182. DOI: 10.1016/j.carpath.2010.12.001.Aikawa E., Whittaker P., Farber M., Mendelson K., Padera R.F., Aikawa M. et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006;113:1344–1352. DOI: 10.1161/CIRCULATIONAHA.105.591768.Aikawa E., Whittaker P., Farber M., Mendelson K., Padera R.F., Aikawa M. et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006;113:1344–1352. DOI: 10.1161/CIRCULATIONAHA.105.591768.Mathieu P., Boulanger M.C. Basic mechanisms of calcific aortic valve disease. Can. J. Cardiol. 2014;30(9):982–993. DOI: 10.1016/j.cjca.2014.03.029.Mathieu P., Boulanger M.C. Basic mechanisms of calcific aortic valve disease. Can. J. Cardiol. 2014;30(9):982–993. DOI: 10.1016/j.cjca.2014.03.029.Liu X., Xu Z. Osteogenesis in calcified aortic valve disease: from histopathological observation towards molecular understanding. Prog. Biophys. Mol. Biol. 2016;122(2):156–161. DOI: 10.1016/j.pbiomolbio.2016.02.002.Liu X., Xu Z. Osteogenesis in calcified aortic valve disease: from histopathological observation towards molecular understanding. Prog. Biophys. Mol. Biol. 2016;122(2):156–161. DOI: 10.1016/j.pbiomolbio.2016.02.002.Monzack E.L., Masters K.S. Can valvular interstitial cells become true osteoblasts? A side-by-side comparison. J. Heart Valve Dis. 2011;20(4):449–463.Monzack E.L., Masters K.S. Can valvular interstitial cells become true osteoblasts? A side-by-side comparison. J. Heart Valve Dis. 2011;20(4):449–463.Mathieu P., Boulanger M.C., Bouchareb R. Molecular biology of calcific aortic valve disease: towards new pharmacological therapies. Expert. Rev. Cardiovasc. Ther. 2014;12(7):851–862. DOI: 10.1586/14779072.2014.923756.Mathieu P., Boulanger M.C., Bouchareb R. Molecular biology of calcific aortic valve disease: towards new pharmacological therapies. Expert. Rev. Cardiovasc. Ther. 2014;12(7):851–862. DOI: 10.1586/14779072.2014.923756.Bosse K., Hans C.P., Zhao N., Koenig S.N., Huang N., Guggilam A. et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. J. Mol. Cell. Cardiol. 2013;60:27–35. DOI: 10.1016/j.yjmcc.2013.04.001.Bosse K., Hans C.P., Zhao N., Koenig S.N., Huang N., Guggilam A. et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. J. Mol. Cell. Cardiol. 2013;60:27–35. DOI: 10.1016/j.yjmcc.2013.04.001.Yip C.Y., Blaser M.C., Mirzaei Z., Zhong X., Simmons C.A. Inhibition of pathological differentiation of valvular interstitial cells by C-type natriuretic peptide. Arterioscler. Thromb. Vasc. Biol. 2011;31(8):1881–1889. DOI: 10.1161/ATVBAHA.111.223974.Yip C.Y., Blaser M.C., Mirzaei Z., Zhong X., Simmons C.A. Inhibition of pathological differentiation of valvular interstitial cells by C-type natriuretic peptide. Arterioscler. Thromb. Vasc. Biol. 2011;31(8):1881–1889. DOI: 10.1161/ATVBAHA.111.223974.Parisi V., Leosco D., Ferro G., Bevilacqua A., Pagano G., de Lucia C. et al. The lipid theory in the pathogenesis of calcific aortic stenosis. Nutr. Metab. Cardiovasc. Dis. 2015;25(6):519–525. DOI: 10.1016/j.numecd.2015.02.001.Parisi V., Leosco D., Ferro G., Bevilacqua A., Pagano G., de Lucia C. et al. The lipid theory in the pathogenesis of calcific aortic stenosis. Nutr. Metab. Cardiovasc. Dis. 2015;25(6):519–525. DOI: 10.1016/j.numecd.2015.02.001.Chen J.H., Chen W.L., Sider K.L. Yip C.Y., Simmons C.A. β-catenin mediates mechanically regulated, transforming growth factor-β1-induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler. Thromb. Vasc. Biol. 2011;31(3):590–597. DOI: 10.1161/ATVBAHA.110.220061.Chen J.H., Chen W.L., Sider K.L. Yip C.Y., Simmons C.A. β-catenin mediates mechanically regulated, transforming growth factor-β1-induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler. Thromb. Vasc. Biol. 2011;31(3):590–597. DOI: 10.1161/ATVBAHA.110.220061.Cadigan K.M. TCFs and Wnt/β-catenin signaling: more than one way to throw the switch. Curr. Top. Dev. Biol. 2012;98:1–34. DOI: 10.1016/B978-0-12-386499-4.00001-X.Cadigan K.M. TCFs and Wnt/β-catenin signaling: more than one way to throw the switch. Curr. Top. Dev. Biol. 2012;98:1–34. DOI: 10.1016/B978-0-12-386499-4.00001-X.Jian H., Shen X., Liu I., Semenov M., He X., Wang X.F. Smad3-dependent nuclear translocation of β-catenin is required for TGF-β1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev. 2006;20(6):666–674. DOI: 10.1101/gad.1388806.Jian H., Shen X., Liu I., Semenov M., He X., Wang X.F. Smad3-dependent nuclear translocation of β-catenin is required for TGF-β1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev. 2006;20(6):666–674. DOI: 10.1101/gad.1388806.Zhang M., Wang M., Tan X., Li T.F., Zhang Y.E., Chen D. Smad3 prevents β-catenin degradation and facilitates β-catenin nuclear translocation in chondrocytes. J. Biol. Chem. 2010;285(12):8703–8710. DOI: 10.1074/jbc.M109.093526.Zhang M., Wang M., Tan X., Li T.F., Zhang Y.E., Chen D. Smad3 prevents β-catenin degradation and facilitates β-catenin nuclear translocation in chondrocytes. J. Biol. Chem. 2010;285(12):8703–8710. DOI: 10.1074/jbc.M109.093526.Shafer S.L., Towler D.A. Transcriptional regulation of SM22α by Wnt3a: convergence with TGFβ(1)/Smad signaling at a novel regulatory element. J. Mol. Cell. Cardiol. 2009;46(5):621–635. DOI: 10.1016/j.yjmcc.2009.01.005.Shafer S.L., Towler D.A. Transcriptional regulation of SM22α by Wnt3a: convergence with TGFβ(1)/Smad signaling at a novel regulatory element. J. Mol. Cell. Cardiol. 2009;46(5):621–635. DOI: 10.1016/j.yjmcc.2009.01.005.Yip C.Y.Y., Chen J.H., Zhao R., Simmons C.A. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 2009;29(6):936–942. DOI: 10.1161/ATVBAHA.108.182394.Yip C.Y.Y., Chen J.H., Zhao R., Simmons C.A. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 2009;29(6):936–942. DOI: 10.1161/ATVBAHA.108.182394.

The authors declare that there are no conflicts of interest present.